1.04
+0.1293(+14.20%)
Currency In USD
| Previous Close | 0.91 |
| Open | 0.97 |
| Day High | 1.07 |
| Day Low | 0.96 |
| 52-Week High | 3.43 |
| 52-Week Low | 0.88 |
| Volume | 795,729 |
| Average Volume | 845,288 |
| Market Cap | 59.02M |
| PE | -0.93 |
| EPS | -1.12 |
| Moving Average 50 Days | 1.37 |
| Moving Average 200 Days | 1.57 |
| Change | 0.13 |
If you invested $1000 in TScan Therapeutics, Inc. (TCRX) since IPO date, it would be worth $99.05 as of December 25, 2025 at a share price of $1.04. Whereas If you bought $1000 worth of TScan Therapeutics, Inc. (TCRX) shares 3 years ago, it would be worth $697.99 as of December 25, 2025 at a share price of $1.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 06, 2025 10:30 PM GMT
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control a
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
GlobeNewswire Inc.
Dec 03, 2025 9:05 PM GMT
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients